Formulation Development
Cellular Origins & Fresenius Kabi Sign Development Agreement for Scalable Automation of Cell & Gene Therapy Manufacturing
Cellular Origins and Fresenius Kabi, an operating company of Fresenius, recently announced they have signed a development agreement that leverages each company’s expertise in cell…
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T Cell Activity & Reduce Important Inflammatory & Fibrotic Drivers in Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently announced the presentation of positive preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary…
Lonza Completes Expansion of New Drug Product Services Facility in Basel (CH)
Lonza recently announced it has enhanced its drug product services offering by adding a new facility for quality control and bioanalytics at its DPS site…
Lipella Pharmaceuticals Announces Patent Allowance for Innovative Liposomal Drug Delivery Platform
Lipella Pharmaceuticals Inc. recently announced the receipt of a notice of allowance from the US Patent and Trademark Office (USPTO) for its proprietary liposomal drug…
Bespak & H&T Presspart Announce Availability of GMP Pilot Line for Low GWP pMDIs
Bespak, a specialist inhalation contract development and manufacturing organization (CDMO), and H&T Presspart, a market leader in the development, manufacturing and supply of inhaled drug…
Impact BioMedical Inc. Announces Issuance of Patent for Linebacker Technology Targeting Inflammatory Disease
Impact BioMedical Inc. recently announced a significant milestone in its innovative Linebacker technology platform. The Canadian Intellectual Property Office has issued Canadian Patent #3,024,728 titled…
Molecure & Ocean Biomedical Sign Exclusive Licensing Agreement for Development & Commercialization of Selective YKL-40 Inhibitors
Molecure S.A. recently signed an exclusive licensing agreement with Ocean Biomedical Inc. concerning the development and commercialization of the selective YKL-40 inhibitor program, including the…
LGM Pharma Expands Analytical Testing Services With New Endotoxin & Rapid Sterility Testing Capabilities
LGM Pharma recently announced today expansion of its Analytical Testing Services (ATS) with the addition of endotoxin and rapid sterility testing capabilities. These new services,…
Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI in Wet AMD
Ocular Therapeutix, Inc. recently announced accelerated timelines for the SOL-1 Phase 3 registrational clinical trial of AXPAXLI in wet age-related macular degeneration (wet AMD). The…
Immuneering Granted Orphan Drug Designation for Pancreatic Cancer Treatment
Immuneering Corporation recently announced the US FDA has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated…
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data
Indaptus Therapeutics, Inc. recently provided an update regarding key clinical advancements in its Phase 1 trial of lead drug candidate Decoy20. The Safety Review Committee…
Akari Therapeutics Announces Effectiveness of Form S-4 & General Meeting Date of November 7, 2024 Related to Peak Bio Merger
Akari Therapeutics, Plc recently announced the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024, related to the merger of…
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
Annovis Bio Inc. recently announced the successful outcome of the End-of-Phase 2 meeting with the US FDA on October 10, 2024. During the meeting, the…
Sapio Sciences Enhances Bioanalysis LIMS & ELN With Advanced Immunogenicity Capabilities
Sapio Sciences recently announced the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform. These new capabilities in the Sapio LIMS (Laboratory Information…
NovaCina Expands Perth Facility to Offer Clinical Supplies Service for Global Market
NovaCina recently announced the expansion of its facility in Perth, Australia with the introduction of a high-tech SA25 GMP filling line to assist customers with small-batch…
Transgene Provides Update on Phase 2 Trial of Therapeutic Cancer Vaccine in Recurrent or Metastatic HPV16-Positive Cervical & Anogenital Cancers
Transgene recently announced its randomized Phase 2 study to evaluate TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive…
Inventiva Announces Financing to Advance NATiV3 Phase 3 MASH Study
Inventiva recently announced financing of immediately €94.1 million and up to €348 million, subject to satisfaction of specified conditions, to fund the completion of the…
Ardena Signs Agreement to Expand US Footprint With Acquisition of Advanced Drug Product Manufacturing Facility
Ardena recently announced it has signed a definitive agreement to acquire Catalent’s state-of-the-art facility in Somerset, NJ. This acquisition will significantly enhance Ardena’s capabilities in downstream…
Honeywell Technology to Power DevPro Biopharma’s Next-Generation Low-Emission Respiratory Inhaler
Honeywell recently announced a long-term supply agreement with DevPro Biopharma to develop a respiratory inhaler that enhances the well-being of patients while reducing carbon emissions associated…
MitoRx Therapeutics Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity
MitoRx Therapeutics recently announced a publication in Elsevier’s prestigious biomedical sciences journal Pharmacological Research. The work led by collaborators at Jagiellonian University Medical College showed…
